Reinnervate and Tecan Sign Co-marketing Agreement
News Nov 27, 2012
Reinnervate Ltd and Tecan Trading AG, have signed a co-marketing agreement to develop a range of automated solutions for 3D cell culture, based on the Freedom EVO® liquid handling workstations and Reinnervate’s Alvetex®Scaffold 3D cell culturing technology.
Alvetex® products are based on a highly porous, polystyrene scaffold structure with a uniform and welldefined architecture that provides an excellent environment for cells to acquire and maintain their natural three-dimensional shape and organization during incubation.
The Alvetex®Scaffold technology therefore gives more biologically relevant data by overcoming the limitations of traditional monolayer cultures.
In combination with the flexibility and reliability of the Freedom EVO platform, it will provide powerful solutions for automated growth and maintenance of 3D cell cultures, allowing researchers to develop more reliable and powerful cellular assays.
Kevin Moore, Head of Applications and Solutions at Tecan, said: “We are delighted to be working with Reinnervate and look forward to combining our mutual expertise and technical abilities to develop ground-breaking solutions for cell biology customers.”
Richard Rowling, Commercial Director at Reinnervate added: “We are delighted that Tecan have decided to put Alvetex®Scaffold at the heart of their plans for the automation of 3D cell culture. We believe that this agreement is great news for cell biologists, as Alvetex®Scaffold is becoming the industry standard for scientists who need to retain the native structure and functionality of cells to better mimic in-vivo biological models.”
IDEX Health & Science Announces Acquisition of New Microfluidics CompanyNews
IDEX Health & Science, LLC announced the acquisition of thinXXS Microtechnology that will accelerate growth of its microfluidics consumables business.READ MORE
Agent Reverses Resistance to Targeted Drug in Some LeukemiasNews
After discovering how some hematologic cancer cells manage to elude death from a targeted therapy, Dana-Farber Cancer Institute scientists have double-crossed the cancer cells with a drug that renders them vulnerable to the targeted agent.READ MORE
New Drug Delivery System Targets Diseases at a Genetic LevelNews
A new drug delivery system that uses a synthetic-biological hybrid nanocapsule could provide a smart technology for targeted treatment of a variety of serious diseases at the genetic level.